Office Address

Wayne State University School of Medicine
Gastroenterology
601 Harper Brush Building
540 E. Canfield
Detroit, Michigan 48201

Office Phone

313-745-8716

Education Training

EDUCATION:

1973-1977 PhD in Biochemistry/Immunology University of Texas Medical Branch Galveston Texas

1970-1972 MA in Chemistry, The Johns Hopkins University, Baltimore MD

1966-1970 BS in Chemistry, Washington College, Chestertown, MD

PROFESSIONAL EXPERIENCE

POSTGRADUATE TRAINING

1980-1982 Post Doctoral and Lecturer Harvard University School of Medicine, Boston, MA

1978-1980 Research Affiliate IV, Department of Experimental Therapeutics, Roswell Park Memorial Institute, Buffalo, New York (Individual National Research Service Award)

BIOTECH EXPERIENCE

2012- present President and Director of Translational Research PHN Biologicals Consulting. Hazel Park, MI

2002-2012 Director of Preclinical Research and Cytokine Biology IRX Therapeutics Inc, Farmingdale, NY (retired after leaving)

FACULTY APPOINTMENTS

2013-present Associate/Assistant Professor, Department of Medicine/Division of Gastroenterology Wayne State University School of Medicine, Detroit, MI

1992 –2002 Associate/Assistant Professor, Department of Medicine/Division of Gastroenterology, Wayne State School of Medicine, Detroit, MI

2000-2002 Adjunct Professor William Tyndale College, Farmington Hills, MI

1983 – 1992 Associate/Assistant Professor, Department of Biochemistry, George Washington University Medical Center, Washington, D.C.

Other Information

MEMPERSHIPS IN PROFESSIONAL ORGANIZATIONS

American Association for the Study of Liver Disease

Publications

REPRESENTATIVE PUBLICATIONS

Hepatitis Research

1. Naylor P.H., Reddy N., Gulati D., Hakim Z., Asbahi R., Ravindran K., Patel S., Tama M., Ehrinpreis MN, Mutchnick MG. Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans with Chronic Hepatitis C. Journal of Clinical and Translational Hepatolology (accepted)

2. Alebouyeh N, Mutchnick S, Bastien M, Ehrinpreis MN, May E, Mutchnick MG. Interferon (IFN) Based Treatment of African Americans with Chronic Hepatitis C (CHC) in an Urban Clinic: Improving Response with Advances in Therapy Paul Naylor, Journal of Gastroenterology and Hepatology Research 2015 February 21 4(2): 1465-1469

3. Siddiqui F, Mutchnick, M., Kinzie, J., Peleman, R., Naylor, P., Ehrinpreis, M.: Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with PCR-confirmed hepatitis C: Implications for vaccination strategy. Amer. J. Gastro 96: 858-863, 2001.

4. Upfal M.J., Naylor P, Mutchnick M.M. Hepatitis C screening and prevalence among urban public safety workers. J Occup Environ Med. Apr;43(4):402-11, 2001

5. Kinzie J.L., Naylor P.H., Nathani M.G., Peleman R.R., Ehrinpreis M.N., Lybik M., Turner J.R., Janisse J.J., Massanari M., Mutchnick M.G.. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat. Jul;8(4):264-9,2001.

6. Yared, G., Hussain, K.B., Nathani, M.G., Moshier, J.A., Dosescu, J., Mutchnick, M.G., Naylor, P.H.: Cytokine mediated inhibition of apoptosis, virus production and anchorage independent growth of viral transfected hepatoblastoma cells. Cytokine 10: 586-595, 1998.

7. Moshier, J.A., Mutchnick, M.G., Dosescu, J., Holtz, T.K., Akkary, S., Mahakala, K., Merline, J.R., Naylor, P.H.: Thymosin 1, but not interferon, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HEPG2 cells. J. Hepatol. 25: 814-820, 1996.

8. Naylor, P.H. Zadaxin (thymosin alpha1) for the treatment of viral hepatitis Expert Opinion on Investigational Drugs 8: 281-287, 1999

Cytokine Biologics

9. Naylor P.H., Naylor C.W. Hernandez K, Dixon A., Brandwein H., Wang CY, Haas, G.P. and J.W: Preclinical Studies with IRX-2 Enhanced Prostate Vaccine, Vaccine 28, 7054- 7062, 2010.

10. Berinstein N., Egan JE., Naylor PH . Peptide based vaccine approaches for cancer- a novel approach using a WT1 synthetic long peptide and the IRX2 immunomodulatory regimen. Cancers, 3, 3991-4009, 2011

11. Berinstein NL; Wolf,G.T; Naylor PH, Baltzer L ;Egan J.E,. Brandwein, Whiteside TL, Goldstein L., El-Naggar A, Badoualn C, et al .Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen,. Immunol Immunother. 2011 Nov 6. [Epub ahead of print]

12. Naylor, P.H. and Hadden JW.H: Preclinical studies with IRX-2 and thymosin alpha 1 in combination therap.y Ann NY Acad Sci 1194. 162-8, 2010.

13. Naylor, P.H. Quadrini K, Garaci E., Rasi G., and Hadden JW. Immunopharmacology of Thymosin α1 and Cytokine Synergy. Ann NY Acad Sci 1112: 235-244, 2007.

14. Naylor, P.H., and Hadden, J.H. T cell Targeted Immune Enhancement Yields Effective T cell Adjuvants. Int. J of Immunopharmacology 3: 1205-1215, 2003.

Vaccine Adjuvant Developmenty

15. Kirkley, J. E., Goldstein, A. L., and Naylor, P. H.: Effect of peptide-carrier coupling on peptide-specific immune responses. Immunobiology 203, 601-615, 2001.

16. Kirkley, J.E., Goldstein, A.L., and Naylor, P.H.: Adjuvant properties of Montanide CSA720 with recombinant protein and synthetic peptide antigens. Scand. J. Immunology 43:431-438,1996.

17. Kirkley, J.E., Naylor, P.H., Marciani, D.J., Kensil, C.R., Newman, M. and Goldstein, A.L.: QS21 augments the antibody response to a synthetic peptide vaccine compared to alum. Combination Therapies (A.L. Godstein and E. Garaci, eds, Plenum Press, N.Y.) pp231-236, 1992.

HIV Vaccine Development

18. Naylor, P.H., Sztein, M., Wada, S., Maurer, S., Holterman, D., Kirkley, J., Naylor, C., Zook, B., Hitzelberg, R., Gibbs, C., Zagury, D., Achour, A., O'Toole, C., Gazzard, B., Youle, M., Rios, A., Sarin, S., Goldstein, A.L.: Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine - HGP-30 - KLH. Int. J. Immunopharmac. 13:117-127, 1991.

19. Sarin, P.S., Sun, D.K., Thorton, A.H., Naylor, P.H. and Goldstein, A.L.: Neutralization of HTLV1. Science 232, 11-14, 1986.

Immunoassays and Mechanism of action

20. Weller, F.E., Mutchnick, M.G., Goldstein, A.L., Naylor, P.H. Enzyme immunoassay measurement of thymosin beta 4 in human serum. J. Biol. Res. Mod., 7:91-96, 1988.

21. Naylor, P.H., Naylor, C.W., Sasaki, D., Mutchnick, M.G.: Utilization of HPLC-ELISA to assess serum levels of thymosin 1 following subcutaneous administration to human subjects. J. Liquid Chromatog. 17: 3541-3551, 1994.

22. Naylor, P.H. Quadrini K, Garaci E., Rasi G., and Hadden JW. Immunopharmacology of Thymosin α1 and Cytokine Synergy. Ann NY Acad Sci 1112: 235-244, 2007.

23. Naylor PH, Oates KK, Coss MC, Erdos MR, Naylor CW, Goldstein AL. Identification of immunoreactive forms of thymosin alpha 1 in serum and supernatants by combining HPLC and RIA. Int J Immunopharmacol. 1992 14:1267-78.

24. Naylor PH, Bhakoo HS, Paolini NS, Goldstein AL, Rosen F. Immunomodulation of murine ß16 melanoma metastasis: Thymosin, thymectomy and irradiation. Thymus 5:355, 1983.

25. Naylor PH, Goldstein AL. Thymosin: Cyclic nucleotides and T-cell differentiation. Life Sciences 25:301, 1979. 

← Return to listing